Table 1.
Demographic and clinical characteristics of the study population.
| ipsilateral |
contralateral |
p-value | |
|---|---|---|---|
| n = 145a | n = 156 | ||
| Years of age (mean ± SD) | 38.5 ± 15.0 | 40.4 ± 15.3 | 0.286e |
| Sex/genderb, n (%) | 0.518f | ||
| male | 80 (55.2) | 91 (58.3) | |
| female | 65 (44.8) | 64 (41.0) | |
| transgender | 0 (0.0) | 1 (0.6) | |
| Weeks between 1st and 2nd vaccination, (mean ± SD) | 5.8 ± 0.7 | 5.8 ± 0.8 | |
| Analysis time [days after 2° vaccination], median (IQR) | 15 (2.0) | 14.5 (1) | |
| Differential blood cell counts | n = 143 | n = 153 | |
| Leukocytes (cells/μl), median (IQR) | 6900 (2400) | 7000 (1800) | 0.825g |
| Granulocytes (cells/μl), median (IQR) | 4080 (1711) | 4092 (1539) | 0.674g |
| Monocytes (cells/μl), median (IQR) | 578 (225) | 594 (192) | 0.786g |
| Lymphocytes (cells/μl), median (IQR) | 2356 (926) | 2317 (826) | 0.774g |
| Thrombocytes (cells/μl), median (IQR) | 257,000 (87,000) | 265,000 (86,000) | 0.272g |
| General lymphocyte subpopulations | n = 63c | n = 77c | |
| CD3 T-cells (cells/μl), median (IQR) | 1670 (659) | 1732 (665) | 0.667g |
| CD4 T-cells (cells/μl), median (IQR) | 991c (553) | 1075 (447) | 0.760g |
| CD8 T-cells (cells/μl), median (IQR) | 436d (327) | 482 (264) | 0.139g |
| CD19 B-cells (cells/μl), median (IQR) | 232 (218) | 224 (144) | 0.947g |
| Plasmablasts (cells/μl), median (IQR) | 0.576 (0.807) | 0.726 (0.643) | 0.207g |
a
Two out of 147 individuals who were included in the ipsilateral group had a positive NCAP-IgG titer (1 male, one female); these two individuals were excluded from further analyses.
b
Self-declared.
c
Determined among subgroup of 143 individuals (64 ipsilateral and 79 contralateral) who were tested for both spike-specific antibodies and T-cells.
d
n = 62.
e
Unpaired t-test.
f
Χ2 test.
g
Mann-Whitney test.